Antisense News and Research

RSS

Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.

Berkeley Lab researchers aim to create biological circuits for synthetic biology

Taking a page from the book of San Francisco radio legend Scoop Nisker, biologists who find themselves dissatisfied with the microbes nature has provided are going out and making some of their own. Members of the fast-growing "synthetic biology" research community are designing and constructing novel organisms and biologically-inspired systems - or redesigning existing organisms and systems - to solve problems that natural systems cannot.

27 May 2011

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the initiation of a Phase 1 clinical study for ISIS-TTRRx.

19 May 2011

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.

11 May 2011

Dravet Syndrome Foundation awards OPKO Health grant to develop potential therapeutic agents

OPKO Health, Inc. announced today that it has been awarded a grant from the Dravet Syndrome Foundation to support the Company's efforts to develop potential therapeutic agents to treat a rare genetic disorder, Dravet Syndrome, also called severe myoclonic epilepsy of infancy, a severe form of epilepsy that usually appears during the first year of life.

9 May 2011

CoDa Therapeutics raises $19.2 million in Series B financing

CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. The company expects further Series B financing with participation from additional investors in a second closing, scheduled for a future date.

18 Apr 2011

Idera's gene-silencing oligonucleotide studies published in Journal of Medicinal Chemistry

Idera Pharmaceuticals, Inc. today announced the online publication in the Journal of Medicinal Chemistry of its studies of a novel class of compounds, which we refer to as gene-silencing oligonucleotides.

18 Apr 2011

EPO grants patent to OncoGenex OGX-427 for prostate cancer treatment

OncoGenex Pharmaceuticals, Inc., today announced that the European Patent Office has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers."

15 Apr 2011

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

OncoGenex presents OGX-427 preclinical data in prostrate cancer at AACR meeting

OncoGenex Pharmaceuticals, Inc. announced today that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011.

5 Apr 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

Rxi's new RNAi preclinical data to be presented at Keystone conference

RXi Pharmaceuticals Corporation, a recognized leader in RNA interference based therapeutic discovery and development, today announced that new preclinical data using proprietary self-delivering RNAi compounds, including RXI-109, will be presented at the Keystone Symposia's Mechanism and Biology of Silencing conference being held March 20-25, 2011 in Monterey, California.

22 Mar 2011

Tiny Locked Nucleic Acid-based compounds inhibit entire disease-associated microRNA families

A study published online in this week's Nature Genetics demonstrates that tiny Locked Nucleic Acid (LNA)-based compounds developed by Santaris Pharma A/S can inhibit entire disease-associated microRNA families. This provides a potential new approach for treating a variety of diseases including cancer, viral infections, cardiovascular and muscle diseases.

21 Mar 2011

Pharmaron signs agreement to provide Isis with nucleoside phosphoramidites up to 100 kg

Pharmaron has signed an agreement to provide Isis Pharmaceuticals, Inc. with nucleoside phosphoramidites at quantities up to 100 kg. Nucleoside phosphoramidites are fundamental building blocks in the production of antisense therapeutics.

17 Mar 2011

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.

1 Mar 2011

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Isis Pharmaceuticals, Inc. announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein in the cohort of subjects in the study with elevated CRP.

24 Feb 2011

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. Tesetaxel, the leading oral taxane in clinical development, will be evaluated for its use as both first- and second-line chemotherapy.

10 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

OPKO Health acquires CURNA

OPKO Health, has acquired CURNA, a privately held company based in Jupiter, Florida, engaged in the discovery of new drugs for the treatment of a wide variety of illnesses, such as cancer, heart disease, metabolic disorders and genetic anomalies.

1 Feb 2011

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, positive data were generated demonstrating that RXi's sd-rxRNA technology can be used, in vitro, to specifically enhance the activity of a microRNA of high interest to miRagen.

28 Jan 2011

GSK and Prosensa commence GSK2402968 Phase III study in DMD

GlaxoSmithKline and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.

20 Jan 2011